SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (5002)8/12/2001 10:31:39 PM
From: Ed Ajootian  Read Replies (1) of 10280
 
Peter,

You say there isn't a whole lotta margin for error on the cash situation. I believe the burn rate for the next few quarters is gonna answer the question of just how much of a margin this is.

In about 4 months SEPR will be able to call another round of their convertible notes if they can get the stock price up to something like $65. If, as a result of lower losses than are currently being projected, they can start buying up the stock in the next few months, this combined with the good news scheduled to come out in that time frame will probably be enough to get the stock price over this hurdle. Once they call those notes and they get converted they are home free as far as the cash situation is. So IMO it behooves them to do everything they can to make sure those notes get converted this December.

For SEPR to lose $.93 this quarter they would have to either dramatically increase R&D expenses over 2Q or their Xopenex sales would have to drop to almost nil.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News